NovoCure (NVCR) reported a Q4 net loss Thursday of $0.61 per diluted share, compared with a loss of $0.45 a year earlier.
Analysts surveyed by FactSet expected a loss of $0.34.
Revenue for the quarter ended Dec. 31 was $161.3 million, compared with $133.8 million a year earlier. Four analysts surveyed by FactSet expected $161.3 million.
NVCR shares were 0.4% lower in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。